NovoCure AI Stock Analysis
Want to see NVCR full AI Analyst Report?
NovoCure (NVCR) AI Stock Analysis
NovoCure
(NASDAQ:NVCR)
NVCR’s score is held back primarily by weak current profitability and negative free cash flow, along with bearish technical trends. Offsetting factors include very strong revenue growth, high gross margins and reduced leverage, plus a constructive earnings outlook with raised guidance; however, the FDA Not Approvable letter for Optune Mya adds material regulatory risk that limits the upside implied by the call.
NovoCure (NVCR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.32B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.52M
- Price to Earnings (P/E)
- -10.7
- Beta (1Y)
- 1.22
- Revenue Growth
- 12.94%
- EPS Growth
- 33.87%
- Country
- US
- Employees
- 1,605
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
NovoCure Business Overview & Revenue Model
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
How the Company Makes Money
NovoCure primarily makes money by selling and providing access to its TTFields therapy devices (e.g., Optune and related TTFields systems) for approved cancer indications. Revenue is generated when eligible patients use the device over time; payment...
NovoCure Earnings Call Summary
The call was strongly positive overall. Management reported record patient levels and revenue, raised 2026 revenue and adjusted EBITDA guidance, delivered substantial year-over-year improvement in profitability metrics, and highlighted momentum in Optune Gio and Optune Lua in Japan. The principal negative issue was the U.S. OptunePax launch slowdown caused by practice disruption and limited access following the introduction of diraxonrasib, alongside a foreign exchange headwind and expected quarter-to-quarter EBITDA variability.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Novocure raised 2026 net revenue guidance to between $736 million and $743 million, representing 12% to 13% growth, including net revenues from Optune Lua and OptunePax collectively between $30 million and $34 million; it expects to maintain gross margin in the mid to high 70s through the final quarter of 2026 and updated full-year adjusted EBITDA guidance to a range of $24 million to $34 million. The company expects to keep R&D costs roughly at or below current levels for the foreseeable future, with 2027 R&D expenses flat to slightly declining, and remains committed to adjusted EBITDA breakeven on a full year basis, with cash flow breakeven as the next goal. It remains committed to delivering double digit top line growth into the future, expects OptunePax to return to growth in the coming quarters, expects a final decision on the Optune Maya PMA application by year end with a potential launch in early 2027, and expects reimbursement for OptunePax in Japan in the first half of 2027, also described as early in 2027 first quarter of 27.
NovoCure Financial Statement Overview
Summary
Financials are improving but still transitional. Revenue growth is very strong and gross margin is robust (~76%), and the balance sheet risk has improved with debt reduced sharply. However, operating and net income remain negative (TTM net margin ~-21%) and free cash flow is still negative (~-$20M), indicating the business is not yet consistently profitable or self-funding.
Income Statement
44NeutralBalance Sheet
63PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 725.39M | 655.35M | 605.22M | 509.34M | 537.84M | 535.03M |
| Gross Profit | 558.67M | 488.47M | 468.04M | 381.06M | 422.97M | 420.15M |
| EBITDA | -104.21M | -121.60M | -109.58M | -177.45M | -67.89M | -38.38M |
| Net Income | -121.73M | -136.23M | -168.63M | -207.04M | -92.53M | -58.35M |
Balance Sheet | ||||||
| Total Assets | 828.71M | 804.33M | 1.24B | 1.15B | 1.19B | 1.14B |
| Cash, Cash Equivalents and Short-Term Investments | 463.48M | 457.52M | 959.87M | 910.62M | 969.42M | 938.51M |
| Total Debt | 231.55M | 290.00M | 683.35M | 596.24M | 584.27M | 581.90M |
| Total Liabilities | 478.10M | 463.86M | 880.61M | 783.63M | 750.48M | 729.00M |
| Stockholders Equity | 350.61M | 340.47M | 360.18M | 362.50M | 441.17M | 410.49M |
Cash Flow | ||||||
| Free Cash Flow | -20.30M | -75.68M | -69.22M | -100.43M | 9.43M | 58.59M |
| Operating Cash Flow | 3.59M | -49.03M | -26.37M | -73.34M | 30.79M | 82.76M |
| Investing Cash Flow | 314.46M | 437.28M | -140.24M | 184.15M | -139.96M | -144.83M |
| Financing Cash Flow | -551.47M | -451.34M | 90.31M | 15.79M | 15.49M | 25.70M |
NovoCure Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCR, the sentiment is Negative. The current price of 11.30 is below the 20-day moving average (MA) of 13.49, below the 50-day MA of 14.70, and below the 200-day MA of 14.79, indicating a bearish trend. The MACD of -0.91 indicates Positive momentum. The RSI at 30.71 is Neutral, neither overbought nor oversold. The STOCH value of 5.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVCR.
NovoCure Risk Analysis
NovoCure disclosed 40 risk factors in its most recent earnings report. NovoCure reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksNovoCure Peers Comparison
Overall Rating
DCTH72Outperform
NVCR49Neutral
SRTS45Neutral
CATX43Neutral
ARAY41Neutral
TLSI37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $691.24M | 111.24 | 5.56% | ― | 38.13% | 709.17% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $1.32B | -10.68 | -35.81% | ― | 12.94% | 33.87% | |
| 45Neutral | $38.52M | -2.41 | -38.65% | ― | -53.33% | -429.93% | |
| 43Neutral | $111.56M | -0.62 | -41.91% | ― | -79.53% | 14.45% | |
| 41Neutral | $7.65M | -0.45 | -36.60% | ― | -12.50% | 5.33% | |
| 37Underperform | $140.06M | -4.62 | 759.69% | ― | 15.38% | 75.82% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVCR | NovoCure Ltd. | 11.30 | -0.15 | -1.31% | |
| ARAY | Accuray Incorporated | 2.55 | -36.32 | -93.44% | |
| DCTH | Delcath Systems, Inc. | 19.87 | 11.22 | 129.71% | |
| CATX | Perspective Therapeutics, Inc. | 0.92 | -1.36 | -59.52% | |
| SRTS | Sensus Healthcare, Inc. | 2.34 | -1.70 | -42.08% | |
| TLSI | Trisalus Life Sciences, Inc. | 2.27 | -2.33 | -50.65% |
NovoCure Corporate Events
NovoCure Receives FDA Not Approvable Letter for Optune Mya
NegativeOn November 9, 2026, Novocure received a Not Approvable Letter from the U.S. Food and Drug Administration for its application seeking approval of Optune Mya for adults with brain metastases from non-small cell lung cancer following stereotactic radia...
NovoCure Gains Japanese Approval for Optune Pax Pancreatic Therapy
PositiveOn October 1, 2026, Novocure reported that Japan’s Ministry of Health, Labour and Welfare approved its Optune Pax device for adult patients with unresectable locally advanced pancreatic cancer, used alongside gemcitabine and nab-paclitaxel. The appro...
NovoCure Announces Routine Board Transition After Director Retirement
NeutralNovoCure Limited announced that director Timothy Scannell retired from its Board, with his seat formally vacated in accordance with the company’s Articles of Association effective September 2, 2026. His departure after five years of service was not t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
